Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Per the activity note to the FY2023 annual report, the company carries out wholesale trade in pharmaceutical products.
| Line item | 2018 | 2019 | 2022 | 2023 | CAGR |
|---|---|---|---|---|---|
| 2,102 | 1,974 | 3,432 | 3,635 | +11.6% | |
| 2,293 | 2,596 | 1,096 | 905 | -17.0% | |
| TOTAL ASSETS | 4,395 | 4,571 | 4,527 | 4,540 | +0.7% |
| 1,036 | 886 | 1,194 | 1,429 | +6.6% | |
| 469 | 1,237 | 471 | 232 | -13.1% | |
| TOTAL LIABILITIES | 1,505 | 2,123 | 1,665 | 1,661 | +2.0% |
| 2,890 | 2,448 | 2,862 | 2,879 | -0.1% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||
| Total Debt | 1,004 | 1,332 | 494 | 221 | -26.1% |
| Cash & Equivalents | 55 | 91 | 91 | 15 | -22.5% |
| Net Debt | 948 | 1,241 | 403 | 206 | -26.3% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set.